Potassium channel changes of peripheral blood T-lymphocytes from Kazakh hypertensive patients in Northwest China and the inhibition effect towards potassium channels by telmisartan

Zhang, Qiubing; Gou, Fang; Zhang, Yuanming; He, Yuanjun; He, Jixian; Peng, Ling; Cheng, Lufeng; Yuan, Qingyan; Zhang, Guiming; Huang, Shasha

doi:10.5603/kp.a2015.0210

Cited by 8 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, healthy subjects were not enrolled and circulating Th17 levels were not measured in this study [7]. Consistent with these results, many clinical studies have found that circulating IL-17 levels significantly increased in hypertensive patients [13, 14]. Moreover, Yao et al found that serum IL-17 levels were significantly higher in subjects with prehypertension, defined as systolic BP of 120 to 139 mm Hg or diastolic BP of 80 to 89 mm Hg, than in subjects with optimal BP, defined as systolic BP < 120 mm Hg and diastolic BP < 80 mm Hg [31].…”

Section: Discussionsupporting

confidence: 57%

“…Data from previous studies revealed that medication use effectively regulates Teff cell activity [5, 6, 11, 14, 20]. Therefore, we analyzed the effect of prehospital medication on effector T cell activity.…”

Section: Discussionmentioning

confidence: 99%

“…However, because data have identified that changes in the Th1, Th2, and Th17 responses exist in atherosclerotic patients with hypertension [11], it is difficult to recognize whether the change in Teff cell activity is associated with hypertension. In addition, many studies suggest that changes in serum levels of IFN- γ , IL-4, and IL-17, which are the characteristic factor of Th1, Th2, and Th17, respectively, may play a role in hypertension [12–14]. Therefore, we investigated the Th1, Th2, and Th17 type responses in 45 patients with primary hypertension in the present study.…”

Section: Introductionmentioning

confidence: 95%

See 2 more Smart Citations

Circulating Th1, Th2, and Th17 Levels in Hypertensive Patients

Cheng

et al. 2017

Disease Markers

View full text Add to dashboard Cite

Background Evidence from experimental studies showed that Th1, Th2, and Th17 play a pivotal role in hypertension and target organ damage. However, whether changes in the circulating Th1, Th2, and Th17 levels are associated with nondipper hypertension and carotid atherosclerotic plaque in hypertension has yet to be investigated. Methods Th1, Th2, and Th17 levels were detected using a flow cytometric analysis, and their related cytokines were measured by enzyme-linked immunosorbent assay in 45 hypertensive patients and 15 normotensive subjects. Results The frequencies of Th1 and Th17 in hypertensive patients, especially in nondipper patients and patients with carotid atherosclerotic plaque, were markedly higher than those in the control group; this was accompanied by higher IFN-γ and IL-17 levels. In contrast, the Th2 frequencies and IL-4 levels in hypertensive patients, especially in nondipper patients and patients with carotid atherosclerotic plaque, were significantly lower than those in the control group. Conclusions The changes in Th1, Th2, and Th17 activity are associated with the onset of the nondipper type and carotid atherosclerotic plaque in hypertensive patients.

show abstract

Section: Discussionsupporting

confidence: 57%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 95%

See 1 more Smart Citation

Circulating Th1, Th2, and Th17 Levels in Hypertensive Patients

Cheng

et al. 2017

Disease Markers

View full text Add to dashboard Cite

show abstract

“…Different types of cardiovascular diseases (CVD) are identified after analysing the accumulated relevant articles, as depicted in Figure 2 . These CVD types are classified into six categories including coronary heart disease [ 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 ], heart failure [ 22 , 26 , 30 , 31 , 32 , 33 , 34 ], arrhythmia [ 29 , 33 , 35 , 36 , 37 , 38 , 39 ], aortic diseases [ 25 , 26 , 29 , 40 , 41 ], and cardiomyopathy [ 26 , 29 , 33 , 42 , 43 ], and only one study for hypertension (HTN) [ 44 ]. Among these finalised 28 articles, the most represented category is coronary heart disease ( n = 14).…”

Section: Resultsmentioning

confidence: 99%

Artificial Intelligence-Based Methods for Precision Cardiovascular Medicine

Mohsen

Al-Saadi

Abdi

et al. 2023

JPM

View full text Add to dashboard Cite

Precision medicine has the potential to revolutionize the way cardiovascular diseases are diagnosed, predicted, and treated by tailoring treatment strategies to the individual characteristics of each patient. Artificial intelligence (AI) has recently emerged as a promising tool for improving the accuracy and efficiency of precision cardiovascular medicine. In this scoping review, we aimed to identify and summarize the current state of the literature on the use of AI in precision cardiovascular medicine. A comprehensive search of electronic databases, including Scopes, Google Scholar, and PubMed, was conducted to identify relevant studies. After applying inclusion and exclusion criteria, a total of 28 studies were included in the review. We found that AI is being increasingly applied in various areas of cardiovascular medicine, including the diagnosis, prognosis of cardiovascular diseases, risk prediction and stratification, and treatment planning. As a result, most of these studies focused on prediction (50%), followed by diagnosis (21%), phenotyping (14%), and risk stratification (14%). A variety of machine learning models were utilized in these studies, with logistic regression being the most used (36%), followed by random forest (32%), support vector machine (25%), and deep learning models such as neural networks (18%). Other models, such as hierarchical clustering (11%), Cox regression (11%), and natural language processing (4%), were also utilized. The data sources used in these studies included electronic health records (79%), imaging data (43%), and omics data (4%). We found that AI is being increasingly applied in various areas of cardiovascular medicine, including the diagnosis, prognosis of cardiovascular diseases, risk prediction and stratification, and treatment planning. The results of the review showed that AI has the potential to improve the performance of cardiovascular disease diagnosis and prognosis, as well as to identify individuals at high risk of developing cardiovascular diseases. However, further research is needed to fully evaluate the clinical utility and effectiveness of AI-based approaches in precision cardiovascular medicine. Overall, our review provided a comprehensive overview of the current state of knowledge in the field of AI-based methods for precision cardiovascular medicine and offered new insights for researchers interested in this research area.

show abstract

“…The pipette solution contained 150.0 mM KCl, 1.0 mM CaCl 2 , 1.0 mM MgCl 2 , 10.0 mM HEPES, and 10.0 mM K 2 EGTA (pH 7.20, adjusted with KOH). The perfusing solution contained 150.0 mM NaCl, 4.5 mM KCl, 1.0 mM CaCl 2 , 1.0 mM MgCl 2 , and 10.0 mM HEPES (pH 7.35, adjusted by NaOH), and Kv1.3 currents were elicited with voltage ramps from -80 to +40 mV of 300-ms duration applied every 30 s, as described previously ( Zhao et al, 2014 ; Zhang et al, 2016 ). Fast and slow capacitances were compensated before every recording.…”

Section: Methodsmentioning

confidence: 99%

Eplerenone Reverses Cardiac Fibrosis via the Suppression of Tregs by Inhibition of Kv1.3 Channel

Shao

Liu

et al. 2018

Front. Physiol.

View full text Add to dashboard Cite

Background: Fibroblast proliferation is a critical feature during heart failure development. Previous studies reported regulatory T-lymphocytes (Tregs)’ protective role against myocardial fibrosis. However, notably, Tregs also secrete fibrogenic cytokine TGF-β when activated. This study aimed to clarify the intriguing link between Tregs and fibrosis, the role of Tregs Kv1.3 potassium channel (regulating T-lymphocytes activation) in the fibrosis process, and how selective aldosterone receptor antagonist Eplerenone affects Tregs and fibrosis through its action on Kv1.3 channel.Methods and Results: After co-incubation with Tregs, cardiac fibroblast proliferation (CCK-8 assay) and levels of collagen I, III, and Matrix metalloproteinase2 (ELISA) significantly elevated. Cell viability assays, Kv1.3 channel mRNA (RT-qPCR), and protein expression (In-Cell Western Blotting) revealed Tregs were activated/proliferated when co-cultured with fibroblasts. Treg intracellular TGF-β level increased by 5.8-fold, far more than that of intracellular IL-10, extracellular TGF-β and IL-10 (ELISA). And 30 μM eplerenone suppressed Tregs proliferation by 82.77% and furthermore, suppressed intracellular TGF-β level to a significantly greater extent than that of intracellular IL-10, extracellular TGF-β and IL-10. Moreover, the Kv1.3 current (whole-cell patch clamp) of Tregs in congestive heart failure patients and rats (induced by coronary artery ligation and exhaustive exercise) elevated by >4-fold than that of healthy volunteers and control rats, whereas 30 μM eplerenone suppressed the current by >60% in control Tregs. In addition, docking calculations (AutoDock software 4.0 suite) showed eplerenone has higher H-bond energy with Kv1.3 channel than other selective blockers.Conclusion: Immuno-regulation in the late stage of CHF activates Tregs proliferation via the upregulation of Kv1.3 channels, which promotes cardiac fibrosis by primarily secreting TGF-β. Taken together, eplerenone’s high affinity to Kv1.3 channel enables it to antagonize the Kv1.3 channels directly to suppress Tregs proliferation, which in turn may play an immuno-regulatory role during CHF.

show abstract

Potassium channel changes of peripheral blood T-lymphocytes from Kazakh hypertensive patients in Northwest China and the inhibition effect towards potassium channels by telmisartan

Cited by 8 publications

References 24 publications

Circulating Th1, Th2, and Th17 Levels in Hypertensive Patients

Circulating Th1, Th2, and Th17 Levels in Hypertensive Patients

Artificial Intelligence-Based Methods for Precision Cardiovascular Medicine

Eplerenone Reverses Cardiac Fibrosis via the Suppression of Tregs by Inhibition of Kv1.3 Channel

Contact Info

Product

Resources

About